BACKGROUND AND OBJECTIVE: Pathogenic mutations in BRCA1/2 tumor suppressor genes increase the lifetime risk for developing breast and ovarian cancer. The aim of the present study was to evaluate the sensitivity and specificity of the Ion Torrent PGM™ for diagnostic mutation screening of BRCA1/2 genes. METHODS: In the current study we included a cohort of 58 Bulgarian high-risk breast cancer patients to validate a next-generation sequencing approach for diagnostic mutation screening of the BRCA1/2 genes using the Ion Torrent Personal Genome Machine® (PGM™) platform. We have also optimized the workflow by comparing two different library preparation methods and using three software packages: NextGENE, Torrent Suite variantCaller, and Samtools/BCFtools to achieve detection of all variants with high specificity and sensitivity. RESULTS: We have validated a quick and accurate diagnostic test, with an overall specificity of 95.9% and sensitivity of up to 100%, which can be the first method of choice, followed by confirmation of the identified variants by Sanger sequencing. Our results prove that the Ion AmpliSeq™ BRCA1/2 Community Panel used with the PGM™ platform, and coupled with our variant selection pipeline, is able to detect all sequence variants discovered by Sanger sequencing. CONCLUSION: The application of the new test which outperforms the classical approach in turn-around time and price will have great impact in the clinical practice to identify the mutation carriers and guide the better personalized treatment of the patients, as well as to contribute for the improved prophylaxis in hereditary breast and ovarian cancer families.
BACKGROUND AND OBJECTIVE: Pathogenic mutations in BRCA1/2tumor suppressor genes increase the lifetime risk for developing breast and ovarian cancer. The aim of the present study was to evaluate the sensitivity and specificity of the Ion Torrent PGM™ for diagnostic mutation screening of BRCA1/2 genes. METHODS: In the current study we included a cohort of 58 Bulgarian high-risk breast cancerpatients to validate a next-generation sequencing approach for diagnostic mutation screening of the BRCA1/2 genes using the Ion Torrent Personal Genome Machine® (PGM™) platform. We have also optimized the workflow by comparing two different library preparation methods and using three software packages: NextGENE, Torrent Suite variantCaller, and Samtools/BCFtools to achieve detection of all variants with high specificity and sensitivity. RESULTS: We have validated a quick and accurate diagnostic test, with an overall specificity of 95.9% and sensitivity of up to 100%, which can be the first method of choice, followed by confirmation of the identified variants by Sanger sequencing. Our results prove that the Ion AmpliSeq™ BRCA1/2 Community Panel used with the PGM™ platform, and coupled with our variant selection pipeline, is able to detect all sequence variants discovered by Sanger sequencing. CONCLUSION: The application of the new test which outperforms the classical approach in turn-around time and price will have great impact in the clinical practice to identify the mutation carriers and guide the better personalized treatment of the patients, as well as to contribute for the improved prophylaxis in hereditary breast and ovarian cancer families.
Authors: Iain Milne; Gordon Stephen; Micha Bayer; Peter J A Cock; Leighton Pritchard; Linda Cardle; Paul D Shaw; David Marshall Journal: Brief Bioinform Date: 2012-03-24 Impact factor: 11.622
Authors: Lídia Feliubadaló; Adriana Lopez-Doriga; Ester Castellsagué; Jesús del Valle; Mireia Menéndez; Eva Tornero; Eva Montes; Raquel Cuesta; Carolina Gómez; Olga Campos; Marta Pineda; Sara González; Victor Moreno; Joan Brunet; Ignacio Blanco; Eduard Serra; Gabriel Capellá; Conxi Lázaro Journal: Eur J Hum Genet Date: 2012-12-19 Impact factor: 4.246
Authors: Christopher J Mattocks; Gemma Watkins; Daniel Ward; Tom Janssens; Ermanno A J Bosgoed; Kim van der Donk; Marjolijn J Ligtenberg; Bruno Pot; Joop Theelen; Nicholas C P Cross; Hans Scheffer; Gert Matthijs Journal: Clin Chem Date: 2010-02-18 Impact factor: 8.327
Authors: Michael A Quail; Miriam Smith; Paul Coupland; Thomas D Otto; Simon R Harris; Thomas R Connor; Anna Bertoni; Harold P Swerdlow; Yong Gu Journal: BMC Genomics Date: 2012-07-24 Impact factor: 3.969
Authors: Lauren M Bragg; Glenn Stone; Margaret K Butler; Philip Hugenholtz; Gene W Tyson Journal: PLoS Comput Biol Date: 2013-04-11 Impact factor: 4.475
Authors: P Cacheiro; A Ordóñez-Ugalde; B Quintáns; S Piñeiro-Hermida; J Amigo; M García-Murias; S I Pascual-Pascual; F Grandas; J Arpa; A Carracedo; M J Sobrido Journal: Mol Diagn Ther Date: 2017-06 Impact factor: 4.074
Authors: Manuele G Muraro; Simone Muenst; Valentina Mele; Luca Quagliata; Giandomenica Iezzi; Alexandar Tzankov; Walter P Weber; Giulio C Spagnoli; Savas D Soysal Journal: Oncoimmunology Date: 2017-05-30 Impact factor: 8.110
Authors: Till Plönes; Walburga Engel-Riedel; Erich Stoelben; Christina Limmroth; Oliver Schildgen; Verena Schildgen Journal: J Pers Med Date: 2016-01-15
Authors: Michael Dean; Joseph Boland; Meredith Yeager; Kate M Im; Lisa Garland; Maria Rodriguez-Herrera; Mylen Perez; Jason Mitchell; David Roberson; Kristine Jones; Hyo Jung Lee; Rebecca Eggebeen; Julie Sawitzke; Sara Bass; Xijun Zhang; Vivian Robles; Celia Hollis; Claudia Barajas; Edna Rath; Candy Arentz; Jose A Figueroa; Diane D Nguyen; Zeina Nahleh Journal: Gigascience Date: 2015-11-04 Impact factor: 6.524